MGF / Mechano Growth Factor

MGF is a splice variant of IGF-1 that is expressed in muscle following exercise or mechanical stress. It promotes satellite cell activation and muscle repair. It has a very short half-life.

PubMed results: 162 · Human studies: 80 · Animal studies: 142

• NCT05536193 — Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris (PHASE4), status: UNKNOWN. Indications: Acne Vulgaris
• NCT05250063 — Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (PHASE2), status: COMPLETED. Indications: Growth Hormone Deficiency
• NCT00600886 — Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly (PHASE3), status: COMPLETED. Indications: Acromegaly
• NCT00171730 — An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly (PHASE2), status: COMPLETED. Indications: Acromegaly
• NCT07286292 — Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation (PHASE2), status: NOT_YET_RECRUITING. Indications: Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
• NCT00497562 — Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) (PHASE2), status: COMPLETED. Indications: Fibromyalgia, Growth Hormone Deficiency
• NCT00444873 — Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly (PHASE3), status: COMPLETED. Indications: Acromegaly
• NCT04400474 — Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (PHASE2), status: COMPLETED. Indications: Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
• NCT00005105 — Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation, status: UNKNOWN. Indications: Intrauterine Growth Retardation
• NCT04358835 — Keto-diet for Intubated Critical Care COVID-19 (NA), status: WITHDRAWN. Indications: COVID-19
• NCT05893641 — Investigate the Relationship Between Exercise Training and Recovery Ratio to Improve Physical Performance and Health Status (PHASE3), status: UNKNOWN. Indications: Exercise, Recovery
• NCT05259969 — Energy Availability in Male Athletes Across the Season, status: UNKNOWN. Indications: Relative Energy Deficiency in Sport
• NCT03690700 — The Feasibility and Effects of Low-load Blood-flow Restricted Exercise Following Spinal Cord Injury (NA), status: UNKNOWN. Indications: Spinal Cord Injuries
• NCT01314859 — Nifedipine Treatment in Preterm Labor (PHASE3), status: WITHDRAWN. Indications: Threatened Preterm Labor
• NCT04710186 — AR, IGF-IR, IR and Peripheral Artery Disease, status: UNKNOWN. Indications: Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect in
• NCT04614337 — Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (PHASE2), status: COMPLETED. Indications: Growth Hormone Deficiency
• NCT01682941 — Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen (NA), status: COMPLETED. Indications: Recurrent Prostate Cancer, Stage IV Prostate Cancer
• NCT01535872 — Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients (PHASE3), status: COMPLETED. Indications: Infertility, Poor Responder to IVF Treatment
• NCT06390670 — The Effect of Colostrum Bovinum Supplementation in Endurance Athletes (PHASE2 / PHASE3), status: COMPLETED. Indications: Sports Nutrition, Biochemical Markers, Exercise Performance, Aerobic Capacity, Supplementation
• NCT06850532 — NMES Effects on Substrate Metabolism and IGF-1 (NA), status: COMPLETED. Indications: The Effects of Neuromuscular Electrical Stimulation on Exercise Performance